Outcomes of CD20 Bispecific Antibodies after CD19 CAR T-cell Therapy in mantle cell lymphoma: A Multicenter Analysis from the Collaborative U.S. Bispecific Consortium (CUBIC)Ajay Major, Andrew Jallouk, Esther Drill et al.|Transplantation and Cellular Therapy|2026Cited by 0
Performance Status Outperforms Comorbidities As Predictor of Survival after Bsabs for Large B cell LymphomaGeoffrey Shouse, Ayushi Chauhan, Jomel Meeko Manzano et al.|Transplantation and Cellular Therapy|2026Cited by 0
Outcomes of Bispecific Antibody Treatment of Double Hit Lymphoma, a Real-World Evidence (RWE) StudyGeoffrey Shouse, Gulrayz Ahmed, Sairah Ahmed et al.|Transplantation and Cellular Therapy|2026Cited by 0
Clinical Outcomes of Lisocabtagene Maraleucel (liso-cel) in Younger Patients (Pts) with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL)Irtiza Sheikh, Sairah Ahmed, Krish Patel et al.|Transplantation and Cellular Therapy|2026Cited by 0